Genentech: Purification of Monoclonal Antibody

Loading...
Thumbnail Image

Authors

Salmon, Arielle

Issue Date

2017

Type

Thesis

Language

en_US

Keywords

Research Projects

Organizational Units

Journal Issue

Alternative Title

Abstract

Lucentis, a monoclonal antibody fragment produced in Escherichia coli, is used to treat wet age-related macular degeneration, one of the leading causes of legal blindness. The objective of this thesis is to analyze the process of antibody fragment separation and to purify a solution of “Lucentis like” protein provided by Genentech to a 99% purity. This paper focuses on the chromatography aspect of the process and investigates the multiple types of chromatography used in both the base case and alternative case presented with a focus on cation exchange chromatography. The project was completed over an eight-month time period spanning two semesters. The team studied various theories, design models, performance equations,, chromatography techniques, literature reviews, and economic analyses. The results obtained from experimental analysis, and after consulting with various teams, instructors, and Genentech employees, highly suggested that the “Lucentis like” protein used was denature and no longer had the properties of the desired protein.

Description

Citation

Publisher

Journal

Volume

Issue

PubMed ID

DOI

ISSN

EISSN